Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: An efficient, dose-adaptive, seamless phase II/III design

Clinical Trials

Volumn 8, Issue 4, 2011, Pages 398-407

  Levin, Bruce ^a   Thompson, John L P ^a   Chakraborty, Bibhas ^a   Levy, Gilberto ^a   MacArthur, Robert ^b   Haley, E Clarke ^c  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TENECTEPLASE;

ANALYTICAL ERROR; ARTICLE; BRAIN ISCHEMIA; DRUG DOSE REGIMEN; HUMAN; MEDICAL DECISION MAKING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANKIN SCALE; SIMULATION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ACUTE DISEASE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG APPROVAL; EARLY TERMINATION OF CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SELECTION BIAS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80051695379     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511410582     Document Type: Article

References (10)

1. Haley EC, Thompson JLP, Grotta JC, et al. Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial. Stroke. 2010 ; 41: 707-711
2. U.S. Department of Health and Human Services Food and Drug Administration, CDER/CBER, February, 2010. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM201790.pdf (accessed 15 September 2010).
3. Levin B, Robbins H. Selecting the highest probability in binomial or multinomial trials. Proc Nat Acad Sci USA. 1981 ; 78: 4663-66
4. Leu CS, Levin B. On the probability of correct selection in the Levin-Robbins sequential elimination procedure. Stat Sin. 1998 ; 9: 879-91
5. Lyden P, Raman R, Liu L, et al. NIHSS training and certification using a new digital video disk is reliable. Stroke. 2005 ; 36: 2446-49 (Pubitemid 41566975)
6. Haley EC, Lyden PD, Johnston KC, Hemmen TM. The TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005 ; 36: 607-12 (Pubitemid 40344164)
7. Graham G. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003 ; 34: 2847-50 (Pubitemid 37517754)
8. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 ; 19: 604-7
9. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979 ; 6: 65-70
10. Fleiss JL, Levin B, Paik MC Statistical Methods for Rates and Proportions. 20033 rd. New YorkWiley. New York: Wiley ; 2003 :